The Quantellect read.As of Nov 19, 2026, 6 active firms cover Corbus Pharmaceuticals Holding: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $30.00 to $48.00, a moderate spread. The average target of $37.50 sits 1264% above the current $2.75. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.21 next quarter toward $-5.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$37.50
+1263.6% upside
Average target across 6 active firms as of Nov 19, 2026 vs $2.75 current
Highest Target$48.00
Average Target$37.50
Lowest Target$30.00
Detailed analyst forecasts for CRBP
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate CRBP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRBP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.21
Range $-1.51 – $-0.96 · 3 analysts · -2% YoY
Next period, 3 analysts expect Corbus Pharmaceuticals Holding to earn $-1.21 a share (range $-1.51 – $-0.96), versus $-1.23 a year earlier. Full-year consensus is $-6.19, growing to $-5.08 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $2.3M next year.
Top analysts covering Corbus Pharmaceuticals Holding
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRBP.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$75.00+2627.3% to target
Overall win rate
45%
+ Follow
#2
Graig Suvannavejh
Mizuho · Rank #239
Buy
$34.00+1136.4% to target
Overall win rate
40%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$35.00+1172.7% to target
Overall win rate
39%
+ Follow
#4
Jeff Jones
Oppenheimer · Rank #320
Buy
$48.00+1645.5% to target
Overall win rate
32%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #404
Buy
$54.00+1863.6% to target
Overall win rate
35%
+ Follow
CRBP stock forecast FAQ
What is CRBP's average 12-month price target?+
The 6 active firms with a live target average $37.50 for Corbus Pharmaceuticals Holding over the next 12 months, ranging from a $48.00 high to a $30.00 low, as of Nov 19, 2026.
Is CRBP stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRBP?+
The Street-high target is $48.00 (Oppenheimer), and the Street-low is $30.00 (Wedbush). The average of all 6 active-firm targets is $37.50.
How many active Wall Street firms cover CRBP?+
6 active firms have a recognized rating on Corbus Pharmaceuticals Holding as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRBP?+
Among analysts who currently cover CRBP, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $75.00 target.
What is Corbus Pharmaceuticals Holding's projected EPS for next quarter?+
The consensus estimate is $-1.21 per share (range $-1.51 – $-0.96) across 3 analysts. Full-year EPS is projected at $-6.19, rising to $-5.08 the following year.
How much revenue is Corbus Pharmaceuticals Holding expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $2.3M next year.
Have analysts been upgrading or downgrading CRBP lately?+
As of Nov 19, 2026, 6 of 6 active firms rate CRBP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRBP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.